Gino Kim In, MD, shares findings from a subgroup analysis of RP1 efficacy in injected and non-injected melanoma lesions after PD-1 inhibitor progression.
Gino Kim In, MD
Advertisement
Gino Kim In, MD, is a medical oncologist, Medical Oncology, Melanoma Surgery, Sarcoma and Melanoma Surgery and associate professor of clinical medicine at USC's Keck School of Medicine.
Articles by Gino Kim In, MD
Advertisement
Latest Updated Articles
Dr In on the Safety and Efficacy of RP1 in Patients With Melanoma Post–PD-1 Inhibitor ProgressionPublished: June 2nd 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5